bioRxivMicrobiologyPreprint
Structural and functional analysis of the Mycobacterium tuberculosis MmpS5L5 efflux pump presages a pathway to increased bedaquiline resistance
Adam J. FountainiD, Jan BöhningiD, Stephen H. McLaughliniD, Tomos E. MorganiD, Paul H. EdelsteiniD, Mark A. TrolliD, Meindert Hugo LamersiD, Tanmay A. M. BharatiD, Ben F. LuisiiD, Lalita RamakrishnaniD
Abstract
Bedaquiline, an antitubercular drug that targets ATP-synthase, is a key component of a new oral drug regimen that has revolutionized the treatment of multi drug resistant tuberculosis. Clinical bedaquiline resistance in Mycobacterium tuberculosis has rapidly emerged, primarily due to mutations in the transcriptional repressor, Rv0678 that result in upregulation of the Resistance-Nodulation-Division (RND) efflux pump MmpS5/MmpL5 (MmpS5L5). Here, to understand how MmpS5L5 effluxes bedaquiline, we determined the structure of the MmpS5L5 complex using cryo-electron microscopy, revealing a novel trimeric architecture distinct from the canonical tripartite RND efflux pumps of Gram-negative bacteria. Structure prediction modelling in conjunction with functional genetic analysis indicates that it uses a periplasmic coiled-coil tube to transport molecules across the cell wall. Structure-guided genetic approaches identify MmpL5 mutations that alter bedaquiline transport; these mutations converge on a region in MmpL5 located in the lower portion of the periplasmic cavity, proximal to the outer leaflet of the inner membrane, suggesting a route for bedaquiline entry into the pump. While currently known clinical resistance to bedaquiline is due to pump upregulation, our findings that several MmpL5 variants increase bedaquiline efflux may presage the emergence of additional modes of clinical resistance. Significance StatementResistance to bedaquiline, a cornerstone drug for treating multidrug-resistant tuberculosis, is rapidly emerging due to mutations that upregulate expression of the MmpS5L5 efflux pump. Here, we reveal the cryo-EM structure of this pump, showing a novel trimeric architecture and a unique -helical coiled-coil tube for drug transport. Structure-guided genetic analysis identifies MmpL5 variants that further increase bedaquiline efflux, suggesting potential resistance mechanisms beyond pump upregulation.
- Citations
- 4
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to potentiate the activity bedaquiline and other antitubercular drugs
Adam J. Fountain, Natalie J.E. Waller, … Lalita Ramakrishnan·bioRxiv·Feb 6, 2025
- Natural product-based putative efflux inhibitors restore bedaquiline susceptibility in a drug-resistant Mycobacterium tuberculosis mutant
Robi Chacha, Maes Valerie, … Elizabeth Kigondu·bioRxiv·Jun 8, 2026
- Structure of mycobacterial ATP synthase with the TB drug bedaquiline
H. Guo, G. M. Courbon, … J. L. Rubinstein·bioRxiv·Aug 6, 2020
- Repeated evolution of bedaquiline resistance in Mycobacterium tuberculosis is driven by truncation of mmpR5
L. W. Roberts, K. M. Malone, … S. V. Omar·bioRxiv·Dec 8, 2022
- Putative MFS transporter Rv1250 of Mycobacterium tuberculosis is involved in multidrug efflux activity
Debasmita Chatterjee, Ajit Ramesh Sawant, … Anindya Sundar Ghosh·bioRxiv·Aug 6, 2025
- Detection of a historic reservoir of bedaquiline / clofazimine resistance associated variants in Mycobacterium tuberculosis
Camus Nimmo, Arturo Torres Ortiz, … Lucy van Dorp·bioRxiv·Oct 6, 2020